Today’s medicines can cost hundreds of thousands of dollars a year.
matthew kapp's insight:
Patients2.0..... Pharma are the innovation engine for disease cures but their customers are the insurance and medical payers, not the patients, and the consumers, needing treatments and cures who ultimately want health not healthcare solutions for being healthy not just cures for when it goes wrong. Today the Healthcare and Pharma system is that, Healthcare not health and it's stacked unfavorably and focused on large population treatments where revenues can match the huge costs of clinical trials in drug development and the self intersts in between . So many diseases get little to no attention and are labeled orphan diseases because there is no payback for the investment needed. In the way social media web 2.0 disrupted the advertising industry with mass personalization through new channels touching the consumers experience, there is an emerging real world trials model that will touch patients and the consumer crowd in the same way. This will cut costs whilst Pharma continue to achieve their 850B$ of revenues, but it will be across many many more treatments and delivering treatments to orphan disease.
Regulations need to adapt to allow technology to change the way markets work advancing development and affordability of treatments for many more diseases.
In the 13 years since the publication of the rough draft of the human genetic code, scientists have run thousands of genome-wide association studies to find links between DNA and disease.
matthew kapp's insight:
This is an example of IT Big Data and Genome sequencing technologies converging and driving exponential results to discovery what DNA and it's expression correlates to a disease as well as a cure. It will help identify the markers for the disease as well as the markers for resistance to the drugs that may be prescribed and a good understanding of how each individual is likely to benefit or not from treatments. Not only can this progress a more precise approach to what drugs can cure or help patients it also can ensure treatments are not unnecessarily prescribed and harming patients. This targeted approach to find the disease markers will save lives, suffering and save billions in health care costs. If not for health, then the later being an economic imperative should result in policy inertia to change impediments in the current system and policies. Disease markers are unique combinations of chemical indicators, such as DNA and proteins, that can be detected in tissue samples. They can indicate a person’s risk of developing a particular form of disease , as well as how they might respond to a specific treatment. Though researchers believe that thousands of clinically useful markers exist, only a handful have been identified to date. As more markers are discovered, doctors will be able to detect disease earlier and personalize treatment based on a patient’s genetic profile – both of which usually result in significantly better treatment outcomes. With pharma's 850b$ a year in revenue generated from an ongoing annual pipeline of only approximately 29 new drugs a year, it takes an expected 22b$ per new drug on average to sustain development. That's not going to scale and tackle all the diseases out there, let alone personalizing drug treatments. This new approach coupled with new adaptive more efficient clinical trial models has the potential to scale massively and pinpoint markers and effective cures, drastically reducing cost for pharma and allowing exponential shift in drug discovery and treating more diseases. The issue is the privacy around our EMR and genetic data. With the potential of ubiquitous DNA data coming available, the opportunity for disease prediction and early treatment is going to be to important. Additionally the potential to not just correlate our DNA with disease but also our environmental exposures, lifestyle, diet and so on will give us much better predictors and alternative types of treatments. While patients may not control how to share their EMR, disease social networks and research sites like PatientsLikeMe with 250,000 critically ill patients, fill the gap and become patient driven research pools of immense value to find these markers.
Surgeons in Swansea, South Wales, have used CT scans to create detailed three-dimensional images which will be used to create the printed implants. (RT @CortesSteve: #3Dprinting used to reconstruct injured man's face, amazing.
Cancer researchers from Rice Univ. have deciphered the operating principles of a genetic switch that cancer cells use to decide when to metastasize and invade other parts of the body. The study found that the on-off switch's ...
Positron emission tomography using F-fluorothymidine as a tracer failed to distinguish true progression of glioblastoma from pseudoprogression in a small single-center study presented at the 2014 ASCO Annual Meeting.
When Stephen Friend formed the nonprofit Sage Bionetworks, his aim was nothing short of revolutionizing the way drug discovery is done so patients don't have to wait for help.
matthew kapp's insight:
"BEFORE WE get to the revolution, let's establish something up front: Medicine is failing us. We're talking mainly here about drug discovery. It takes too long to develop new drugs; it costs too much; and the drugs that make it out of the pipeline work for only about half the people who take them."
In health care, I can envision having a system where one trades privacy for premium fees.
matthew kapp's insight:
With heath costs spiraling out of control as the system is basically stacked against patients driving health care not health, open Big Data mining can bring about an evidence based measures to not only drive lower cost of treatments but to drive preventative medicine and more effectively target cures to personalised medicine. Population data matched against efficacy of what treatments work and health problem early warning signals will have tremendous benefits to research, treatments, costs and longevity with better health. Transparency will transform healthcare. Anonymity should be protected but there will be risks just as we have seen in other areas. Can we really choose no to our populations better health and no to lowering the economic burden that's inflationary spiral will cripple our economies.
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.